Imagion Biosystems has announced a notification to ineligible shareholders regarding the renounceable pro-rata offer of 28 October 2019.
Read the notification.
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
